A股申购 | 北芯生命(688712.SH)开启申购 专注于心血管疾病诊疗领域

Company Overview - Beixin Life (688712.SH) focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with an emphasis on developing transformative solutions for cardiovascular care [1] - The company has launched 11 products to the market and has 6 products in development, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [1] Key Products - The core product, the IVUS system, is China's first domestically developed 60MHz high-definition and high-speed IVUS product, characterized by high definition, speed, and intelligence, facilitating precise PCI strategy formulation [1] - The FFR measurement system is the first domestically approved product in China for the gold standard FFR field, both products are undergoing special review procedures for innovative medical devices, potentially revolutionizing clinical practices in PCI surgeries [1] Market Position - After launching, the core products quickly captured the second-largest market share domestically and the largest share among domestic brands, contributing to the increase in the localization rate of high-end active interventional medical devices [1] Financial Performance - Revenue for the years 2022, 2023, 2024, and the first half of 2025 is approximately 92.45 million, 184 million, 317 million, and 259 million RMB respectively, with net profits of -300 million, -155 million, -53.74 million, and 45.51 million RMB for the same periods [2] - As of June 30, 2025, total assets are approximately 838.54 million RMB, with equity attributable to the parent company at about 755.23 million RMB and a consolidated debt-to-asset ratio of 15.20% [3]